While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, others are continuing and pushing regulatory boundaries.

Over the past five years, licensing deals in the U.S. have averaged $84.8 billion. In China? Just $31.3 billion. Even with ...

U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data ...